Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Precision BioSciences

Biotech & Life Sciences · Durham, United States · Founded 2006 · IPO 2019 Thoroughbred

A gene editing company specializing in in vivo gene editing with its ARCUS platform

Valuation
$98M
Market cap · May/2026
Revenue
$34M
Latest reported FY

Investors

18 investors on Precision BioSciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
F-Prime
venBio Partners
Amgen Ventures
Osage University Partners
RA Capital Management
Ziegler Group
Baxter Ventures
Longevity Fund
Series B+ 10 investors entered at this stage
Pontifax AgTech
Agent Capital
Cormorant Asset Management
Franklin Templeton Investments
Alexandria Venture Investments
Vivo Capital
ArrowMark Partners
Brace Pharma
Adage Capital
Transformation Capital

Global footprint

Where Precision BioSciences has talent and traffic

AI talent share
2.1% of workforce is AI talent
(2 of 96 staff)
Core AI00%
Other AI22.08%
Non-AI workforce9497.92%
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
9K monthly visits
across markets
🇺🇸 United States78.9%
🇮🇳 India7.8%
🇬🇧 United Kingdom7.8%
🇨🇦 Canada3.3%
🇵🇭 Philippines2.2%
Top 5 markets shown

Market sentiment

What the market is saying about Precision BioSciences

An AI-synthesized read of the highest-engagement posts about Precision BioSciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Precision BioSciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.